Growth Hormone AxisResearch OnlyNot For Human Consumption

Ipamorelin

GHRP-1 analogue · NNC 26-0161

Triggers growth hormone release with minimal side effects, often paired with CJC-1295 for a cleaner, more powerful GH pulse.

MECHANISM OF ACTION

Ipamorelin is a five-amino-acid peptide that tells the pituitary gland to release a pulse of growth hormone. What makes it stand out from older growth hormone releasers (like GHRP-2 or GHRP-6) is that it does this without raising cortisol (the stress hormone) or prolactin (a hormone that can cause unwanted effects at high levels). This makes it one of the cleaner options in its class. It's commonly combined with CJC-1295: CJC-1295 lifts the overall level of growth hormone activity, and Ipamorelin then triggers well-timed pulses on top of that, a complementary pairing.

RESEARCH APPLICATIONS

  • Selective GH pulse stimulation
  • Body composition - lean/fat ratio studies
  • Sleep quality and nocturnal GH pulse research
  • Combination GHRH/GHRP synergy modelling
  • Bone mineral density (preclinical)

RESEARCH HIGHLIGHTS

Selectivity vs. Earlier GHRPs

1998

Head-to-head in swine models: ipamorelin produced equivalent GH release to GHRP-6 with significantly lower ACTH and cortisol - superior chronic safety profile.

Ref: Raun et al., Eur J Endocrinol

BMD Preservation

2000

12-week ipamorelin in preclinical bone-loss models showed statistically significant BMD preservation vs. control via IGF-1-mediated osteoblast activity.

Ref: Svensson et al., Growth Horm IGF Res

RESEARCH PROTOCOL NOTES

Physical formSupplied lyophilised (freeze-dried powder) unless stated otherwise
ReconstitutionBacteriostatic water; swirl gently, do not shake
HandlingProtect from light; avoid repeated freeze-thaw cycles

Chemical Identity

Molecular FormulaC38H49N9O5
Molecular Weight711.9 g/mol
CAS Number170851-70-4
SolubilitySoluble in bacteriostatic water

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Storage & Stability

Lyophilised: -20°C or 2–8°C. Reconstituted: 2–8°C, 28 days. More stable in solution than CJC-1295.

Regulatory Status

No regulatory approval. WADA prohibited (S2). SAHPRA: unscheduled research compound.

Important - read before proceeding

This page is a summary of published scientific literature about a molecule. It is provided for research and educational purposes only. Nothing on this page is medical advice, a diagnosis, a recommendation, a prescription, or a claim that this compound treats, cures, prevents or improves any condition in humans. Research findings described here are observations reported by third-party researchers about the molecule - they are not statements about the product supplied by Bio Intelligence, and they should not be read as an expected outcome.

Compounds supplied are not registered medicines, have not been evaluated by SAHPRA, and are not for human consumption. No dosing, route of administration or usage guidance is provided by Bio Intelligence. If you have a health concern, speak to a registered healthcare practitioner.